非小细胞肺癌患者血清血管内皮生长因子和基质金属蛋白酶9水平与转移及预后的关系
摘要
非小细胞肺癌(NSCLC)是最常见的一种肺癌,约占所有肺癌的85%。大约2/3的NSCLC被诊断为晚期肺癌,虽然抗肿瘤药物层出不穷,但是在过去几十年间肺癌患者的预后并无显著改善,而NSCLC的发病机制也尚未完全揭示。血管生成和淋巴结转移是NSCI,C肿瘤生长和迁移的关键因素,
出处
《临床荟萃》
CAS
2011年第23期2066-2068,共3页
Clinical Focus
参考文献10
-
1Giovannetti E, Erdem L, Olcay E, et al. Influence of polymorphisms on EGFR targeted therapy in non small-cell lung cancer[J]. Front Biosci, 2011,16 : 116-130.
-
2Gasparini G, Longo R, Toi Met al. Angiogenic inhibitors:a new therapeutic strategy in oncology[J]. Nat Clin Pract Oncol, 2005,2(11) :562-577.
-
3Ueda M, Terai Y, Kanda K, et al. Tumor angiogenesis and molecular target therapy in ovarian earcinomas[J]. Hum Cell, 2005,18(1) : 1-16.
-
4Ferrara N,Gerber HP,LeCouter J,et al. The biology of VEGFand its receptors[J]. Nat Med,2003,9(6):669-676.
-
5孙丽娟,秦超,岳慧萍.CYFRA21-1、CA19-9、VEGF联合检测对非小细胞肺癌临床诊断价值的探讨[J].当代医学,2011,17(12):41-43. 被引量:10
-
6Anagnostou VK, Tiniakos DG, Fotinou M, et al. Multiplexed analysis ofangiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients[J]. Virchows Arch, 2011,458(3) : 331-340.
-
7Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer[J]. N Engl J Med,2006,355(24) :2542-2550.
-
8Parson SL, Watson SA, Brown PD, et al. Matrix metalloproteinases[J]. Br J Surg,1997,84(2) :160-166.
-
9Jin G, Miao R, Hu Z, et al. Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population [J]. Int J Cancer, 2009,124(9) :2172-2178.
-
10Mihaylova ZH, Ludovini V, Gregorg V, et al. Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients[J]. J Balk Union Oncol, 2007,12 ( 1 ) 105-111.
二级参考文献8
-
1Saksmoto K,Haga Y Yoskimurea R, et al. CompAraWve effectivenessof the tumour diagnostic CA19-9,OA125 and ca:cinoembryonic antigen in patients with disease of digestive system[J].Out, g87,28:525.
-
2Holmgrem J,Ifndholm L,person B,et al,Peection by monoclonalantibody of carbohydrate antigen CA50 in serum of patients with carcinoma[J]. Br Med J,1984,288;1479.
-
3Ohshio G,Yamaki K.Imamura T,et aI.Distribution the csrbohydrateAntigens, Du-PA N-Z and CAI 9-9 in tumor of the lung[J]. Tumori, 1995,8: 67.
-
4Skobe M, Hawighorsit T, Jackson DG, et al. Induction oftumorlymphang iogenesis by VEGF--cpromotesbreast cancer metastasis[J]. Nat Med 2001 7(2):192 ;98.
-
5Gerber HP, Ferrar N. The role of VEOF in normai and neopJastichemaa:opoiesis[J]. J iviol Med,2005,81(]):20.
-
6李春海.加强肿瘤生物学标志的研究和评价[J].中华检验医学杂志,2000,23(1):6-8. 被引量:101
-
7曾波航,李丹,黄慧,吕嘉春,于宪,邬勇坚.非小细胞肺癌患者血清CYFRA_(21-1)和CEA的临床应用[J].肿瘤防治研究,2001,28(6):421-423. 被引量:17
-
8王广义,王旭,谭毓铨.血管内皮生长因子及其受体与肿瘤生长的研究进展[J].吉林大学学报(医学版),2004,30(2):316-317. 被引量:11
共引文献9
-
1沈建人.CEA、CYFRA21-1、CA125检测在肺癌诊断中的应用[J].肿瘤学杂志,2012,18(4):311-312. 被引量:1
-
2王一帆,毕清,任宏轩.联合检测血清肿瘤标志物诊断非小细胞肺癌的研究进展[J].南昌大学学报(医学版),2013,53(1):76-78. 被引量:14
-
3王远.肿瘤标记物检测对非小细胞肺癌临床诊断价值的探讨[J].齐齐哈尔医学院学报,2013,34(4):525-526.
-
4何志惠,苏群豪,洪涛,曾江正,雷俊华.非小细胞肺癌P-gp、LRP表达及其与预后的相关性[J].中国老年学杂志,2013,33(16):3832-3833. 被引量:1
-
5陈淑云,顾文刚,于莉.联合检测血清肿瘤标志物对非小细胞肺癌的诊断价值[J].武警医学,2013,24(10):887-888. 被引量:7
-
6潘洁,毕怡,任玉欣,曹峰林,张大昕.血清细胞角蛋白19片段、肿瘤相关糖链抗原、血管内皮生长因子联合检测诊断非小细胞肺癌的价值[J].现代中西医结合杂志,2015,24(12):1340-1341. 被引量:11
-
7刘志强,王湘毅,孙晓革,仝兴亚,张国锋,沈洋.CA125,CA153及CEA肿瘤标志物联合检测对非小细胞肺癌早期诊断的临床意义[J].临床合理用药杂志,2016,9(5):111-112. 被引量:12
-
8方安平,王建屏,何艳芬,李琳慧.长春瑞滨联合顺铂治疗晚期非小细胞肺癌疗效观察[J].当代医学,2016,22(14):146-147. 被引量:3
-
9陈玲玲,林勇,叶小凯,许圣威,曹晓红,林宜亭,翁朝航,姜燕,柯明耀.血清CEA、CYFRA21-1及TSGF在肺癌化疗前后的表达变化及意义[J].实用癌症杂志,2017,32(12):1928-1930. 被引量:11